EORTC

E2-RADIatE Oligo Care cohort, largest prospective registry cohort on oligometastatic disease – EORTC

EORTC shared a post on LinkedIn:

“We are excited to share a new publication about the E2-RADIatE Oligo Care cohort, the largest prospective registry cohort on oligometastatic disease.

This interim analysis of approximately 1600 oligometastatic patients aimed to evaluate acute toxicity within 6 months following stereotactic body radiotherapy (SBRT).

Toxicity within 6 months was low, confirming that SBRT is safe to use in the oligometastatic setting.”

E2-RADIatE Oligo Care cohort, largest prospective registry cohort on oligometastatic disease – EORTC

For more information.

Source: EORTC/LinkedIn

cancer EORTC - European Organisation for Research and Treatment of Cancer oligometastatic disease OncoDaily Oncology Stereotactic Body Radiotherapy